Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). 
History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 gram of alcohol: a half-pint (approximately 240 milliliter [mL]) of beer, 1 glass (100 mL) of wine or 1 (25 mL) measure of spirits. 
History of sensitivity to heparin or heparin-induced thrombocytopenia. 
History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation. 
Gastrointestinal disease or with gastrointestinal surgical history which can affect the absorption of the investigational product. 
A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening 
Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening. 
A positive pre-study drug/alcohol screen. 
A positive test for Human Immunodeficiency Virus (HIV) antibody. 
Pregnant females as determined by positive serum hCG test at screening or prior to dosing. 
Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 90 day period. 
Lactating females. 
The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 90 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). 
Exposure to more than four new chemical entities within 12 months prior to the first dosing day.       
    

NCT02201316_exc_T1
Temporal
Current
NCT02201316_exc_T2
Temporal
chronic
NCT02201316_exc_T3
Observation
history
NCT02201316_exc_T4
Condition
liver disease
NCT02201316_exc_T5
Scope
Current or chronic
NCT02201316_exc_T6
Condition
biliary abnormalities
NCT02201316_exc_T7
Condition
hepatic abnormalities
NCT02201316_exc_T8
Condition
Gilbert's syndrome
NCT02201316_exc_T9
Negation
exception
NCT02201316_exc_T10
Condition
gallstones
NCT02201316_exc_T11
Qualifier
asymptomatic
NCT02201316_exc_T12
Scope
with the exception of Gilbert's syndrome or asymptomatic gallstones)
NCT02201316_exc_T13
Scope
liver disease, or known hepatic or biliary abnormalities
NCT02201316_exc_T14
Condition
regular alcohol consumption
NCT02201316_exc_T15
Observation
History
NCT02201316_exc_T16
Temporal
within 6 months of the study
NCT02201316_exc_T17
Reference_point
the study
NCT02201316_exc_T18
Measurement
average weekly intake
NCT02201316_exc_T19
Value
>21 units
NCT02201316_exc_T20
Person
males
NCT02201316_exc_T21
Value
>14 units
NCT02201316_exc_T22
Person
females
NCT02201316_exc_T23
Scope
>21 units for males or >14 units for females
NCT02201316_exc_T25
Condition
sensitivity to heparin
NCT02201316_exc_T26
Drug
heparin
NCT02201316_exc_T27
Condition
heparin-induced thrombocytopenia
NCT02201316_exc_T28
Qualifier
heparin-induced
NCT02201316_exc_T29
Drug
heparin
NCT02201316_exc_T30
Drug
study medications
NCT02201316_exc_T32
Condition
sensitivity to any of the study medications
NCT02201316_exc_T34
Observation
History
NCT02201316_exc_T35
Condition
drug allergy
NCT02201316_exc_T36
Condition
allergy
NCT02201316_exc_T40
Condition
Gastrointestinal disease
NCT02201316_exc_T41
Observation
gastrointestinal surgical history
NCT02201316_exc_T42
Procedure
gastrointestinal surgical
NCT02201316_exc_T43
Qualifier
affect the absorption of the investigational product
NCT02201316_exc_T46
Measurement
Hepatitis B surface antigen
NCT02201316_exc_T47
Value
positive
NCT02201316_exc_T48
Temporal
pre-study
NCT02201316_exc_T49
Measurement
Hepatitis C antibody
NCT02201316_exc_T50
Value
positive
NCT02201316_exc_T51
Temporal
within 3 months of screening
NCT02201316_exc_T52
Reference_point
screening
NCT02201316_exc_T53
Scope
positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
NCT02201316_exc_T55
Measurement
Urinary cotinine levels
NCT02201316_exc_T56
Condition
smoking
NCT02201316_exc_T57
Condition
regular use of tobacco
NCT02201316_exc_T58
Observation
history
NCT02201316_exc_T59
Condition
regular use of nicotine-containing products
NCT02201316_exc_T60
Temporal
within 6 months prior to screening
NCT02201316_exc_T61
Reference_point
screening
NCT02201316_exc_T62
Scope
Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products
NCT02201316_exc_T63
Temporal
pre-study
NCT02201316_exc_T64
Measurement
drug screen
NCT02201316_exc_T65
Measurement
alcohol screen
NCT02201316_exc_T66
Scope
drug/alcohol screen
NCT02201316_exc_T67
Value
positive
NCT02201316_exc_T68
Measurement
Human Immunodeficiency Virus (HIV) antibody
NCT02201316_exc_T69
Value
positive
NCT02201316_exc_T70
Condition
Pregnant
NCT02201316_exc_T71
Person
females
NCT02201316_exc_T72
Measurement
serum hCG test
NCT02201316_exc_T73
Value
positive
NCT02201316_exc_T74
Temporal
at screening
NCT02201316_exc_T75
Temporal
prior to dosing
NCT02201316_exc_T76
Reference_point
screening
NCT02201316_exc_T77
Reference_point
dosing
NCT02201316_exc_T78
Scope
at screening or prior to dosing
NCT02201316_exc_T82
Person
females
NCT02201316_exc_T83
Condition
Lactating
NCT02201316_exc_T86
Multiplier
more than four
NCT02201316_exc_T87
Drug
new chemical entities
NCT02201316_exc_T89
Temporal
within 12 months prior to the first dosing day
NCT02201316_exc_T90
Reference_point
the first dosing day